Century Therapeutics, Inc.
IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also deā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.98
Price-2.23%
-$0.04
1Y
Price
Market Cap
$170.975m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR+550.5%
3y CAGR+398.6%
5y CAGREarnings
-$107.779m
-1025.0%
1y CAGR-308.4%
3y CAGR-232.4%
5y CAGREPS
-$1.25
-1036.4%
1y CAGR-304.4%
3y CAGR-228.6%
5y CAGRBook Value
$264.744m
$326.553m
Assets$61.809m
Liabilities$48.025m
DebtDebt to Assets
14.7%
-0.5x
Debt to EBITDAFree Cash Flow
-$95.908m
+8.4%
1y CAGR+1.8%
3y CAGR-127.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company